Cariprazine and Nirogacestat: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 16, 2026 · Source data updated Jul 16, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Cariprazine
Nirogacestat
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Here's what's going on. Your body clears cariprazine (Vraylar) using a liver enzyme called CYP3A4. Nirogacestat (Ogsiveo) slows that enzyme down. When it's slowed, cariprazine and its active breakdown product build up in your body, which can mean stronger effects and more side effects like restlessness, drowsiness, trouble sleeping, or movement changes.
The good news: this is very manageable. Your care team can simply use a lower cariprazine dose while you're on nirogacestat, and adjust it back later if nirogacestat is stopped. Please don't change anything on your own. Just check in with your pharmacist or doctor so they can tailor your dose safely.
Mechanism: Cariprazine is a CYP3A4 substrate; nirogacestat is a moderate CYP3A4 inhibitor. Inhibition reduces metabolism, increasing exposure to cariprazine and its long-acting active metabolite didesmethylcariprazine (DDCAR). Neither is a relevant prodrug here, so this raises, not lowers, drug effect.
Direction/magnitude: increased AUC/Cmax; severity major, evidence probable.
Management (per labeling):
- Reduce cariprazine dose when combined with a moderate CYP3A4 inhibitor.
- Schizophrenia/bipolar mania: initiate 1.5 mg every other day; titrate per response.
- Stable 1.5 or 3 mg daily: switch to 1.5 mg every other day; stable 4.5 or 6 mg daily: switch to 1.5 mg once daily.
- Monitor for EPS, akathisia, sedation. On inhibitor discontinuation, dose may need increasing per response.
What happens
Increased cariprazine and its major active metabolite (didesmethylcariprazine (DDCAR)) exposure
Interaction Deep Dive
Taking cariprazine (a CYP3A4 substrate) together with a moderate CYP3A4 inhibitor can raise the levels of both cariprazine and its active metabolite, didesmethylcariprazine. If cariprazine therapy is being started in a patient already receiving a moderate CYP3A4 inhibitor (for schizophrenia or bipolar mania), begin with 1.5 mg orally every other day; this may be raised to 1.5 mg orally every other day if warranted, guided by clinical response and how well it is tolerated. For those on a moderate CYP3A4 inhibitor being treated for bipolar depression or adjunctive treatment of MDD, the dose is 1.5 mg orally every other day. When a moderate CYP3A4 inhibitor is added to a patient already stabilized on cariprazine, dosing should be modified as follows: for patients presently taking 1.5 or 3 mg once daily, change cariprazine to 1.5 mg orally every other day upon starting the moderate inhibitor; for patients presently taking cariprazine 4.5 or 6 mg once daily, change to 1.5 mg orally once daily upon starting the moderate inhibitor. Once the moderate CYP3A4 inhibitor is stopped, an increase in the cariprazine dose may be warranted, based on clinical response and tolerability1.
Why it happens (mechanism)
Inhibition of CYP3A4-mediated metabolism of cariprazine
How to manage this interaction
Keep taking both medicines as prescribed unless your care team tells you otherwise. This combination is well understood and can be managed with dosing adjustments.
- Your prescriber will likely lower your cariprazine dose while you are on nirogacestat, since your specific target dose depends on your current dose and what you are being treated for.
- Your team may watch you more closely for side effects like restlessness, muscle stiffness, or drowsiness.
- If nirogacestat is ever stopped, your cariprazine dose may be raised again based on how you respond.
Ask your pharmacist or doctor before changing anything, and report new or worsening symptoms.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
1 report — tap to read
a) In drug interaction studies, giving cariprazine 1.5 mg/day together with erythromycin (a moderate CYP3A4 inhibitor) 500 mg twice daily over 21 days led to an increase in cariprazine AUC (0 to 24 hours) and Cmax of roughly 50% 1. In one study that enrolled only White males receiving cariprazine 1.5 mg/day and erythromycin 500 mg twice daily (n=40), AUCs rose by 38% (cariprazine), 11% (desmethylcariprazine, an active metabolite), and 60% (didesmethylcariprazine, an active metabolite), and Cmax rose by 34%, 16%, and 62%, respectively. Tmax was not affected by coadministration with erythromycin 2.
Common questions
Can I take Cariprazine and Nirogacestat together?
Nirogacestat slows the breakdown of cariprazine, raising its levels, so your cariprazine dose will likely be lowered while you take both. Keep taking both as prescribed and let your pharmacist or doctor adjust and monitor your dose. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Cariprazine and Nirogacestat interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Cariprazine and Nirogacestat interaction managed?
Keep taking both medicines as prescribed unless your care team tells you otherwise. This combination is well understood and can be managed with dosing adjustments. Your prescriber will likely lower your cariprazine dose while you are on nirogacestat, since your specific target dose depends on your current dose and what you are being treated for. Your team may watch you more closely for side effect… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Cariprazine or Nirogacestat need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (2)
- Product Information: VRAYLAR(R) oral capsules, cariprazine oral capsules. AbbVie Inc. (per FDA), North Chicago, IL, 2024. DailyMed
- Szabo M, Hujber Z, Harsanyi J, et al: Coadministration of cariprazine with a moderate CYP3A4 inhibitor in patients with schizophrenia: implications for dose adjustment and safety monitoring. Clin Pharmacokinet 2024; 63(10):1501-1510. PubMed
Keep reading about Cariprazine
Keep reading about Nirogacestat
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist